In this Leading article, we summarize current knowledge of the occurrence of the first and so far only transferable colistin resistance gene, mcr-1. Its location on a conjugative plasmid is likely to have driven its spread into a range of enteric bacteria in humans and animals. Screening studies have identified mcr-1 in five of the seven continents and retrospective studies in China have identified this gene in Escherichia coli originally isolated in the 1980s, while the first European isolate dates back to 2005. Based on the widespread use of colistin in pigs and poultry in several countries and the higher number of mcr-1-carrying isolates of animal origin than of human origin, it is tempting to assume that this resistance may have emerged in the animal sector. Whatever its origin, interventions to reduce its further spread will require an integrated global one-health approach, comprising robust antibiotic stewardship to reduce unnecessary colistin use, improved infection prevention, and control and surveillance of colistin usage and resistance in both veterinary and human medicine.
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Initial observations
Whenever a novel antibiotic resistance emerges, there is a need to assess its potential clinical and public health impact. One newly reported resistance where such an assessment is clearly required is transferable plasmid-encoded resistance to colistin mediated by the mcr-1 gene. Colistin was introduced into clinical use in the 1950s, but due to its perceived nephrotoxicity and neurotoxicity, its use had greatly diminished by the 1980s, with the exception of nebulized administration to cystic fibrosis patients with lung infections and gut decontamination regimens used in intensive care. 1 However, the increasing problem posed by MDR Gram-negative bacteria, coupled with a relative paucity of new antibiotics active against such strains, has led not only to a resurgence in the use of colistin, but the WHO has now included colistin in its list of critically important antibiotics. 2 Although phenotypic resistance to colistin had been described prior to the discovery of mcr-1, 3,4 such resistance was chromosomally encoded, and hence spread entailed either de novo emergence or clonal expansion of resistant isolates. However, in late 2015, a report was published that described for the first time transferable colistin resistance encoded by the mcr-1 gene located on a conjugative plasmid in Escherichia coli. 5 This report was significant, not only for describing a novel mechanism of colistin resistance (production of a phosphoethanolamine transferase) that was transferable, but also for the finding of colistin-resistant E. coli in retail meat, pigs at slaughter and in infected humans. The observation that mcr-1-positive bacteria were more frequently observed in animals and food of animal origin led to the suggestion that this new resistance gene had spread from the veterinary to the human domain.
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The next steps Following on from the publication of the nucleotide sequence of mcr-1, numerous research groups were able to rapidly screen archived bacterial DNA sequences for the presence of the gene. This resulted in a rash of reports of the detection of the mcr-1 gene in different countries on five continents: Asia (China, 5,8 -18 Cambodia, 19 Japan, 20 Laos, 21 Malaysia, 8, 22, 23 Taiwan, 24 Thailand 21 and Vietnam 25 -27 ), Europe (Belgium, 28, 29 Denmark, 30 France, 21,31 -33 Germany, 34 Great Britain, 35, 36 Italy, 37, 38 Lithunia, 39 Poland, 40 35 The location of mcr-1 on mainly conjugative plasmids, which transfer in part at rather high frequencies, 5 may explain its occurrence in different enterobacterial species. Plasmid analysis revealed that occasionally plasmids similar in structure to the original plasmid pHNSHP45 5 have been detected in Salmonella Typhimurium, 36 K. pneumoniae 19 and E. coli. 19, 59 Other reports, however, detected mcr-1 on structurally diverse plasmids in E. coli. 29, 36, 60 Many of the mcr-1-carrying plasmids also harbour other resistance genes, including ESBL genes and carbapenemase genes among others. 10,11,16,28,29,32,34 -37,60 -63 The co-location of mcr-1 with 
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other resistance genes on conjugative plasmids supports the co-transfer and the persistence of mcr-1 under the selective pressure imposed by the use of non-polypeptide antimicrobial agents. These findings were notable not only for the widespread geographical occurrence of a range of mcr-1-positive Gramnegative bacteria, but also for the fact that the mcr-1 gene was found in isolates dating from as long ago as the 1980s. 14 Thus, the phenomenon of transferable colistin resistance had been around for more than 25 years, but without being detected. This suggests little previous clinical and public health impact over the previous decades since any major incidents or outbreaks would likely have triggered active laboratory investigations.
The future
Increases in infections due to MDR Gram-negative bacteria, particularly those resistant to carbapenems, are likely to lead to greater reliance on colistin for treatment until new antibiotics with activity against these bacteria become available. In terms of assessing the future risk, a number of factors need to be considered, many of which will require active surveillance and research. Clearly the relative contribution of resistance in animals, food, the environment and humans (both colonized and infected patients) needs delineation if we are to fully understand the underlying epidemiology. Such knowledge is essential if we are to devise rational interventions aimed at reducing or even halting the future spread of colistin resistance. This will require a multidisciplinary approach: molecular biology is needed to better understand the inter-strain/species spread of plasmids containing mcr-1 and to seek its presence in the gut microbiome of both animals and humans; surveillance of the prevalence of colistin resistance and usage in both veterinary and human medicine and the associations between them (including the use of other antibiotics to which colistin-resistant bacteria are also resistant) are needed to inform antibiotic prescribing and stewardship policies to optimize clinical outcomes while trying to minimize resistance; and classical surveillance activities are also needed to identify risk factors in both human and animal populations to inform policy and intervention strategies.
Finally, an important factor in dealing with problems of antibiotic resistance is the dissemination of information. The current issue of the Journal of Antimicrobial Chemotherapy contains numerous articles on various aspects of colistin resistance and efficacy. They include: two newly developed real-time PCR assays for diagnosis; 64, 65 a report about the veterinary sector as the most likely origin of mcr-1;
6 the evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing K. pneumoniae; 66 reports about the isolation of E. coli carrying mcr-1 from a pig farm in Belgium; 29 the isolation of mcr-1-positive E. coli from humans and retail meats between 2010 and 2015 in Taiwan; 24 the detection of mcr-1 in E. coli and S. enterica serovars from livestock and meat in the Netherlands; 47 the finding of mcr-1 in S. enterica from retail meat in Portugal;
41 a report about mcr-1 in S. enterica serovars and E. coli from a pig farm in Great Britain; 36 the detection of the mcr-1 gene in 27 the co-location of mcr-1 and an ESBL gene on the same plasmid in S. enterica;
63 the presence of mcr-1-positive E. coli in wild birds; 39, 55 and the presence of E. coli carrying mcr-1 in Poland. 40 In addition, there is a paper reporting a high rate of colistin dependence in Acinetobacter baumannii from hospitals in Korea. 67 Moreover, a report of a pharmacokinetic/pharmacodynamic model based on in vitro time -kill data for predicting the in vivo PK/PD index of colistin has been published in this journal recently. 68 Hopefully, this level of generation and dissemination of new information is indicative of the response of the international research community to the threat posed by colistin resistance and the need to develop interventions to control its future spread.
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